Raymond Sanchez joined Cerevel Therapeutics in 2019 as chief medical officer, overseeing clinical development of the company’s pipeline.
Raymond joins Cerevel Therapeutics from Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC), where he most recently served as senior vice president, global clinical development and was also appointed as chief medical officer of Avanir Pharmaceuticals during the last half of his 11-year tenure at Otsuka. In his role at OPDC, Raymond was responsible for the oversight of the company’s CNS, oncology, and cardio-renal development portfolio, managing early-stage development through post-marketing commitments for all programs under his purview. Previously, Raymond served in leadership roles at Bristol-Myers Squibb and Purdue Pharma.
Raymond is currently the executive co-chair of the International Society for CNS Drug Development (ISCDD) and trustee, member of the Board of Directors for the Connecticut Mental Health Center Foundation, Yale School of Medicine, as well as several other not-for-profit organizations. Throughout his career, Raymond has authored dozens of publications in leading medical journals and received many honors and awards for his leadership and commitment to the advancement of medicine.
Raymond received a bachelor’s degree from the Weinberg College of Arts and Sciences at Northwestern University and a medical degree from the Feinberg School of Medicine at Northwestern. He completed his residency training and fellowship in psychiatry at the Yale University Medical School, where he was also appointed as an instructor.